MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Supernus Pharmaceuticals DPO Ratio 2011-2026 | SUPN
Annual DPO Ratio Supernus Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.8 | 15.3 | 27.2 | 41.6 | 37.6 | 56.7 | 222 | 75.9 | 164 | 245 | 187 | 118 | 6.05 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.05 K | 15.3 | 559 |
Quarterly DPO Ratio Supernus Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 39.4 | 41.5 | 33.8 | - | 28.6 | 48.5 | 45.8 | - | 18.1 | 34.5 | 43 | - | 90.9 | 107 | 55.1 | - | 41.3 | 24 | 36.9 | - | 26.2 | 66.9 | 179 | - | 192 | 229 | 165 | - | 69.3 | 79.2 | 140 | - | 147 | 162 | 231 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 231 | 18.1 | 87.9 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.56 | 2.13 % | $ 3.74 B |  USA |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Akebia Therapeutics
AKBA
|
168 | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alnylam Pharmaceuticals
ALNY
|
55 | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
186 | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Avid Bioservices
CDMO
|
62.3 | - | - | $ 789 M | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
4.06 K | $ 32.41 | 3.38 % | $ 2.15 B | USA |
 |
Chimerix
CMRX
|
2.38 K | - | - | $ 756 M | USA |